13/03/2014 14:08 AST
A leading Saudi-based pharmaceutical company is set to hold its second cardiovascular convention in Colombo on Friday.
The Convention (2nd TCC), organized by the Tabuk Pharmaceuticals Manufacturing Company is set to create a think tank for discussing the current scenario of cardiovascular diseases (CVD) that are prevalent in the MENA (Middle East and North Africa) region. The Convention will look into the challenges being faced by modern cardiologists and the latest advancements in the field of cardiology.
TCC is an event organized by Tabuk Pharmaceuticals across the Middle-East and North-Africa region but is completely led by and dedicated to physicians.
It aims to raise awareness of the dangers and implications of cardiovascular conditions in the MENA region, to foster collaboration between key opinion leaders (KOLs) to help curb the CVD burden in the region and to share the latest knowledge and insights.
“In the MENA region, 45 percent of the total deaths are caused by coronary artery disease where dyslipidemia is the single largest cardiovascular disease risk factor and high blood pressure is the second leading cause of death and disability in this region,” Dr. Haitham Baghdadi, M.D., Corporate Medical Affairs Manager, Tabuk Pharmaceuticals said. “The TCC experts will highlight these serious problems and recommend effective methods to improve care for cardiovascular patients and help them maintain healthier hearts and enjoy a better life,” he added.
Talking about the role of Tabuk Pharmaceuticals, Faisal Al-Bashr, its corporate communication manager, said, “Tabuk Pharmaceuticals, as a leading Saudi pharmaceutical company, will act as a strategic partner in enhancing knowledge transfer and improving patient care. Our role is not only to provide medicines but is also extended to making significant contributions in education and awareness.”
Tabuk Pharmaceuticals Manufacturing Company develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally. Established in 1994 in Saudi Arabia, Tabuk Pharmaceuticals’ fast growth has allowed it to become a global company, with a strong focus on the Middle-East and North-Africa region. Today, Tabuk Pharmaceuticals has a presence in over 20 markets and employs approximately 2,000 employees. It operates in multiple therapeutic areas including the central nervous system disease, (CNS) cardiovascular, anti-infection, respiratory, and the muscular skeletal system.
Tabuk Pharmaceuticals’ distinctive marketing capabilities, state-of-the-art manufacturing facilities, broad product portfolio, deep understanding of pharmaceutical regulations, and strong partnerships and affiliations, have helped create a leading pharmaceutical player in the MENA region.
Its standing as one of the largest Arab pharmaceutical companies, and the first Saudi Pharmaceutical Company to obtain the EU-GMP certification, is a tribute to competencies and know-how.
Tabuk Pharmaceuticals’ aims are to consistently exceed the patients’ demands by providing them with the best quality drugs at affordable prices.
Tabuk Pharmaceuticals is a fully owned subsidiary of Astra Industrial Group (AIG), a public trading company on the Saudi stock exchange.
Arab News
Please wait...
